[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595986":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":30,"overallOfficials":39,"centralContacts":47,"locations":53,"responsibleParty":83,"collaborators":13,"id":85,"slug":13,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":13,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":13,"enrollmentInfo":93,"targetDuration":13,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":13,"overallStatus":55,"whyStopped":13,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"To evaluate the efficacy after CM336 treatment","Hematologic complete response (hCR) rate","up to 3 years",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21,26],{"label":22,"type":23,"description":13,"interventionNames":24},"Low dose group(CM336)","EXPERIMENTAL",[25],"Biological: CM336 Injection(Low dose group)",{"label":27,"type":23,"description":13,"interventionNames":28},"High dose group(CM336)",[29],"Biological: CM336 Injection(High dose group)",[31,36],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":13},"BIOLOGICAL","CM336 Injection(Low dose group)","subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.",[22],{"type":32,"name":37,"description":34,"armGroupLabels":38,"otherNames":13},"CM336 Injection(High dose group)",[27],[40,44],{"name":41,"affiliation":42,"role":43},"Jian Li","Peking Union Medical College Hospital","PRINCIPAL_INVESTIGATOR",{"name":45,"affiliation":46,"role":43},"Gang An","Institute of Hematology & Blood Diseases Hospital, China",[48],{"name":49,"role":50,"phone":51,"phoneExt":13,"email":52},"Qian Jia","CONTACT","028-88610620","qianjia@keymedbio.com",[54,70],{"facility":42,"status":55,"city":56,"state":57,"zip":13,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":61,"coordinates":62},"Point",[63,64],116.39723,39.9075,{"lat":64,"lon":63},[67],{"name":41,"role":50,"phone":68,"phoneExt":13,"email":69},"86+18610852525","lijian@pumch.cn",{"facility":71,"status":55,"city":72,"state":73,"zip":13,"country":58,"countryCode":59,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Institute of Hematology & Blood Diseases Hospital","Tianjin","Tianjin Municipality",{"type":61,"coordinates":75},[76,77],117.17667,39.14222,{"lat":77,"lon":76},[80],{"name":45,"role":50,"phone":81,"phoneExt":13,"email":82},"86+13502181109","angang@ihcams.ac.cn",{"type":84,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100595986",false,"NCT07039578","Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis","An Open-Label, Multi-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Relapsed or Refractory Primary Light-Chain Amyloidosis","Inclusion Criteria:\n\n* Voluntary provision of written informed consent and ability to comply with protocol requirements.\n* Age ≥18 years, any gender.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n* Confirmed diagnosis of primary light-chain (AL) amyloidosis.\n* Relapsed or refractory primary AL amyloidosis.\n* Measurable hematologic disease at screening (per protocol-defined criteria).\n* Involvement of ≥1 amyloid-affected organ.\n* Adequate organ function meeting all protocol-specified criteria within 3 days prior to first dose.\n\nExclusion Criteria:\n\n* Current or prior diagnosis of multiple myeloma.\n* Received anti-AL amyloidosis therapy within protocol-specified timeframe prior to first dose.\n* Clinically significant cardiovascular or cerebrovascular disease.\n* Any active or uncontrolled infection meeting protocol-defined criteria.\n* Any other condition deemed by the Investigator to preclude safe study participation.","ALL","18 Years",{"count":94,"type":95},90,"ESTIMATED","INTERVENTIONAL",[98],"PHASE2","to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis",[101],"Primary Light-Chain Amyloidosis","2025-11-20",{"date":104,"type":105},"2025-11-26","ACTUAL",{"date":107,"type":105},"2025-07-25",{"date":109,"type":95},"2029-07-31",{"name":5,"class":6},2]